Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA6 | P23280 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA3 | P07451 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA5A | P35218 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2814300 | 0.97 | — | — | |
| SCHEMBL27706726 | 0.86 | CA12 (0.48) | ACE2CXCR4CA12CA6CA7 | |
| SCHEMBL23067998 | 0.86 | — | — | |
| SCHEMBL2336421 | 0.86 | ACE2 (0.40) | ACE2CA12CA6CA7CA9 | |
| SCHEMBL947067 | 0.85 | CASP2 (0.36) | ACE2CA12CA6CA7CA9 | |
| SCHEMBL3968889 | 0.83 | CA12 (0.50) | ACE2CA12CA6CA7CA9 | |
| SCHEMBL5501507 | 0.83 | CA12 (0.39) | ACE2CA12CA6CA7CA9 | |
| SCHEMBL28518647 | 0.81 | GNAI3 (0.40) | CA12CA6CA7CA9CA14 | |
| SCHEMBL17740072 | 0.78 | GNAI3 (0.41) | CA12CA6CA7CA9CA14 | |
| SCHEMBL947315 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115895508-A | Adhesive film composition, packaging adhesive film and photovoltaic module | 杭州福斯特应用材料股份有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-115011046-A | Anti-fatigue flame-retardant PVC (polyvinyl chloride) plastic boot | 安徽冠泓塑业有限公司 | 2022-09-06 | — | — | CN | claimed |
| CN-111892757-A | Water-tree-resistant polyolefin cable material and preparation method thereof | 浙江太湖远大新材料股份有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-116410637-B | Rare earth antibacterial and antiviral rare earth finishing paint and application thereof | 杭州开物鑫工程技术有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-116410637-A | Rare earth antibacterial and antiviral rare earth finishing paint and application thereof | 杭州开物鑫工程技术有限公司 | 2023-07-11 | — | — | CN | disclosed |
| CN-115895508-A | Adhesive film composition, packaging adhesive film and photovoltaic module | 杭州福斯特应用材料股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-115011046-A | Anti-fatigue flame-retardant PVC (polyvinyl chloride) plastic boot | 安徽冠泓塑业有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-108912468-B | Anti-aging bubble film and forming process thereof | 厦门协四方工贸有限公司 | 2021-03-19 | — | — | CN | disclosed |
| CN-111892757-A | Water-tree-resistant polyolefin cable material and preparation method thereof | 浙江太湖远大新材料股份有限公司 | 2020-11-06 | — | — | CN | disclosed |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2019-02-12 | — | — | US | disclosed |
| CN-109233045-A | A kind of EPE packaging material and preparation method thereof and protective case | 厦门市地隆包装材料有限公司 | 2019-01-18 | — | — | CN | disclosed |
| EP-1385577-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. Hoffman-la Roche AG (CH) | 2004-02-04 | — | — | EP | disclosed |
| US-20030158187-A1 | Isolated nucleic acids, a diagnostic kit, sequence identification, gene sequence determination, a computer program with stored sequence information | F. HOFFMANN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-08-21 | — | — | US | disclosed |
| WO-2003064685-A2 | GENETIC POLYMORPHISMS IN THE PREPROTACHYKININ GENE | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
| CN-1426302-A | Method for treating brain, spinal cord and nerve injury | HOFFMANN LA ROCHE (CH) | 2003-06-25 | — | — | CN | disclosed |
| US-20030109417-A1 | Brain, spinal, and nerve injury treament | EUSTRALIS PHARMACEUTICALS LIMITED (AU) | 2003-06-12 | — | — | US | disclosed |
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | F. HOFFMANN-LA ROCHE AG (CH) | 2003-01-02 | — | — | US | disclosed |
| EP-1261335-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F.HOFFMANN-LA ROCHE AG (CH) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002085458-A2 | USE OF NK-1 RECEPTOR ANTAGONISTS AGAINST BENIGN PROSTATIC HYPERPLASIA | F. HOFFMAN-LA ROCHE AG (CH) | 2002-10-31 | — | — | WO | disclosed |
| WO-2001052844-A1 | BRAIN, SPINAL AND NERVE INJURY TREATMENT | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004157-A1 | Use of NK-1 receptor antagonists against benign prostatic hyperplasia | KLK3, TACR1, TACR2 | ACE2 2329/4885CXCR4 1099/4885CA12 4580/4885 |
| US-10201568-B2 | Brain, spinal, and nerve injury treatment | TACR1, TACR2, NPSR1 | ACE2 1966/4885CXCR4 832/4885CA12 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.